The AVITA Medical Inc (ASX: AVH) share price has plunged in opening trade today after the company released its second-quarter results for the fiscal year 2021.
At the time of writing, the AVITA share price is trading at 5.85% lower at $6.55.
AVITA Medical is a regenerative medicine group that aims to address unmet medical needs in burn injuries, trauma injuries, chronic wounds and dermatological and aesthetics indications. The company endeavours to advance care for burn patients with its novel technology platform, the RECELL System. AVITA is also listed on the NASDAQ stock exchange in the United States under the ticker RCEL.
Let’s take a look at its quarterly results for the period ended 31 December 2020.
Financial results
The company reported a US-based RECELL revenue of $5.0 million. This is a 62% increase compared to the same quarter of the prior year.
Total global revenue increased 57% compared to the previous corresponding period (pcp), coming in at $5.1 million.
Operating expenses decreased to $10.4 million for the period compared to $13.4 million in the pcp. AVITA attributes the savings partially to lower legal costs and lower stock-based compensation.
As of 31 December 2020, the company held $59.8 million in cash.
AVITA did not provide financial guidance due to current uncertainty stemming from coronavirus. The company advised that because it gained its revenue via 20 accounts with physicians, its accounts were susceptible to the impacts of COVID-19. This was currently creating an unpredictable business space.
AVITA reported a net loss of $5.6 million for the quarter, compared to the net loss of $10.5 million for the same quarter in the previous year.
CEO commentary and AVITA share price snapshot
AVITA Medical CEO Dr Mike Perry made the following comments:
I’m proud of our progress over the last quarter as we strive to broaden the applications of our platform to serve patients. With our burn centre account base now mostly built out, our sales team is poised and ready to drive utilisation as the pandemic abates and we regain access to hospitals and patients.
We have continued to make strong progress with our vitiligo pivotal trial, seeing very encouraging interest and enrolment trends, and we believe this could put us in a position to file for FDA approval in 2022.
The AVITA Medical share price has fallen more than 56% over the previous 12-month period. Year-to-date, the share price has gained around 44%.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
- Here are the 10 most shorted shares on the ASX
- GameStop effect: 3 more shorted ASX shares that could skyrocket
- Here are the 10 most shorted shares on the ASX
- Here are the 10 most shorted shares on the ASX
- Here are the 10 most shorted shares on the ASX
Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post The AVITA Medical (ASX: AVH) share price plummets almost 6% in early trade appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3jIenax
Leave a Reply